Supported by the NIH,No.DK118334 and No.AG064869;and the BrightFocus,No.A2019630S(to Sun Y).
BACKGROUND Antagonists of cannabinoid type 1 receptor(CB1)have been shown to promote body weight loss and improve insulin sensitivity.Cannabinoids decrease adiponectin,and CB1 blocker increase adiponectin.However,the ...